Advertisement


Ian Chau, MD, on Esophageal and Gastric Cancers: Systemic Agents and Options

2017 Gastrointestinal Cancers Symposium

Advertisement

Ian Chau, MD, of the Royal Marsden Hospital, discusses the continuum of care in esophageal and gastric cancers and the multiple active lines of treatment. Routine adoption of genomic testing may lead to further refinement of current treatment and more options in the future.



Related Videos

Pancreatic Cancer

Mark Talamonti, MD, on Pancreatic Cancer: Minimally Invasive Resection

Mark Talamonti, MD, of NorthShore University Health System, discusses the technical prerequisites for minimally invasive surgery in pancreatic cancers and the potential benefits to patients.

Gastrointestinal Cancer

Salah-Eddin Al-Batran, MD, on Gastric Cancer: RADPAC Trial Results

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses study findings on paclitaxel with and without RAD001 in patients with gastric cancer whose disease has progressed after therapy with a fluoropyrimidine/platinum-containing regimen (Abstract 4).

Colorectal Cancer

Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).

Gastroesophageal Cancer

Geoffrey Ku, MD, MBA, on Gastric and Esophageal Cancers: Expert Perspectives on Immunotherapy

Geoffrey Ku, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy drugs and the search for biomarkers that will help identify patients more likely to respond, not only to these medications, but to combinations of immunotherapies, other targeted treatments, chemotherapy drugs, and radiation.

Colorectal Cancer

Cathy Eng, MD, on Anal Squamous Cell Cancer: Management Strategies

Cathy Eng, MD, of The University of Texas MD Anderson Cancer Center, discusses management approaches to anal cancer, including the current standard of care, as well as novel approaches for locally advanced and metastatic disease.

Advertisement

Advertisement




Advertisement